Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

Childhood acute myeloid leukemia (AML) is the second most common leukemia in children, but causes the majority of leukemia related deaths. Current therapies do not adequately treat the disease and more than half of all children diagnosed with AML eventually relapse and die of their disease. Dr. Meshinchi recently performed a comprehensive genetic analysis of pediatric AML and identified mutations in CSF3R gene, the first pediatric-specific mutation in AML. This JJ's Angels St. Baldrick's Research Grant aims to study the function of this mutation to learn how it might be used as a therapeutic target.

This grant is named for the JJ's Angels Hero Fund created in memory of Julianna LaMonica to honor her joyful spirit and strength even in the midst of her battle with cancer. Her story continues to inspire so many to support the cause.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

By increasing physical activity, survivors may reduce their risk of obesity and chronic diseases, and improve their quality of life. Dr. Mendoza's research aims to examine the use of a wearable physical activity device, the Fitbit, paired with a Facebook group, to increase physical activity among teen childhood cancer survivors. This approach aims to harness new wearable technology and the widespread use of smart phones to use individual- and peer-influences to promote physical activity.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Rhabdomyosarcoma is an aggressive childhood cancer that often arises in muscle. Because of the poor survival, researchers are searching for genes underlying this cancer, with the hope of blocking them. A research scientist who studies how normal muscle forms found that a gene called MEST helps in defining muscle cell precursor identity. Dr. Linardic's lab had noticed that in rhabdomyosarcoma, MEST was highly expressed, suggesting that maybe MEST tricks cells into constantly growing. This project focuses on learning how MEST contributes to rhabdomyosarcoma, and how to block it.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

Alveolar rhabdomyosarcoma (aRMS) is a cancer of the soft tissues. This disease often responds to chemotherapy, but in many patients available treatments fail. Dr. Keller's lab identified how a cancer-causing gene called Pax3:Foxo1 leads to treatment failure. Remarkably, Pax3:Foxo1 can be silenced by entinostat, a drug recently granted FDA breakthrough designation for breast cancer. Dr. Keller has found that entinostat dramatically improves sensitivity to chemotherapy, but efficacy in relapsed disease is unknown. This research aims to identify whether entinostat makes relapsed aRMS sensitive to chemotherapy, paving the way for an evidence-based clinical trial that could save lives.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

Based on progress to date, Dr. Kalish was awarded a new grant in 2018 to fund an additional year of this Scholar grant. Beckwith-Wiedemann syndrome (BWS) is a genetic disorder that affects thousands of children. Up to 25% of children with BWS develop cancer, most commonly liver and kidney cancer. The same genetic changes that cause BWS also cause other types of cancer, however we do not currently understand how. Dr. Kalish's research is studying how genetic changes that cause BWS lead to cancer using a large group of BWS patients and models. The goal of this research is to use the knowledge gained from these models to improve care for patients with BWS and related cancers.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Late Effects After High Risk Neuroblastoma – The LEAHRN Study. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL